1-Methoxy-3-Ethoxybenzene

1-Methoxy-3-Ethoxybenzene

SCHEMBL1068417

CCOc1cccc(OC)c1

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.61
TP53 P04637 1/20 0.61
MAOB P27338 7/20 0.60
LMNA P02545 2/20 0.58
MAPK1 P28482 4/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C19 P33261 2/20 0.56
CYP2D6 P10635 1/20 0.56
TSHR P16473 2/20 0.55
APP P05067 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
ALDH1A1 P00352 2/20 0.53
TDP1 Q9NUW8 1/20 0.53
ACHE P22303 1/20 0.52
ESR1 P03372 2/20 0.52
AHR P35869 1/20 0.52
MEN1 O00255 1/20 0.51
CYP2C9 P11712 1/20 0.51
RECQL P46063 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,3-Diethoxybenzene SCHEMBL1100167 0.91 TP53 (0.71) CYP3A4TP53LMNAMAPK1CYP1A2
1-Methoxy-3-Ethoxybenzene SCHEMBL17167773 0.85 TP53 (0.55) CYP3A4TP53MAOBLMNAMAPK1
1-Hydroxy-3-Ethoxybenzene SCHEMBL8073061 0.85 CHRNB2 (0.51) CYP3A4TP53MAOBLMNAMAPK1
SCHEMBL1729519 0.84 MAPK1 (0.75) CYP3A4MAOBLMNAMAPK1CYP1A2
SCHEMBL11306471 0.84 MAOB (0.62) CYP3A4MAOBLMNAMAPK1TSHR
SCHEMBL9488001 0.84 TP53 (0.63) CYP3A4TP53LMNAMAPK1CYP1A2
1-Methoxy-3-Propoxybenzene SCHEMBL791921 0.83 MAPK1 (0.62) CYP3A4MAOBLMNAMAPK1CYP1A2
1,3-Dimethoxybenzene SCHEMBL901285 0.83 ACHE (0.70) CYP3A4MAOBLMNACYP1A2CYP2C19
1,3-Dimethoxybenzene SCHEMBL9350 0.83 ACHE (0.70) CYP3A4MAOBLMNACYP1A2CYP2C19
SCHEMBL5038332 0.82 MAPK1 (0.62) CYP3A4MAOBLMNAMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119384454-A Depolymerization process of polymers containing ester functionalities using mixed organic solvents 韩国化学研究院 2025-01-28 CN claimed
WO-2024005445-A1 METHOD FOR DEPOLYMERIZATION OF POLYMER CONTAINING ESTER FUNCTIONAL GROUP BY USING MIXTURE ORGANIC SOLVENT 한국화학연구원 2024-01-04 WO claimed
CN-110144139-A A kind of zinc oxide base nano particle ink and photoelectric device 纳晶科技股份有限公司 2019-08-20 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-9620718-B2 Method for preparing a semiconducting layer CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2017-04-11 US claimed
US-9293711-B2 Organic semiconductor formulations POLYERA CORPORATION (US) 2016-03-22 US claimed
US-20150188053-A1 METHOD FOR PREPARING A SEMICONDUCTING LAYER CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2015-07-02 US claimed
CN-103613487-B Method for preparing alpha-alkylated ketone by coupling alcohol with alpha-methyl/methylene ketone UNIV NORTHWEST NORMAL 2015-06-17 CN claimed
WO-2013190255-A9 METHOD FOR PREPARING A SEMICONDUCTING LAYER CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2015-01-08 WO claimed
CN-103613487-A Method for preparing alpha-alkylated ketone by coupling alcohol with alpha-methyl/methylene ketone UNIV NORTHWEST NORMAL 2014-03-05 CN claimed
WO-2013190255-A2 METHOD FOR PREPARING A SEMICONDUCTING LAYER CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2013-12-27 WO claimed
CN-120040272-A Method for producing m-ethyl anisole and p-ethyl anisole by using xylenol oil 煤炭科学技术研究院有限公司 2025-05-27 CN disclosed
CN-117820088-B Preparation method of m-ethylanisole 万华化学集团股份有限公司 2025-02-18 CN disclosed
CN-119384454-A Depolymerization process of polymers containing ester functionalities using mixed organic solvents 韩国化学研究院 2025-01-28 CN disclosed
CN-117820088-A Preparation method of m-ethylanisole 万华化学集团股份有限公司 2024-04-05 CN disclosed
US-5459142-A Autoimmune disease, atherosclerosis, antiischemic agents and nephritis OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1995-10-17 US disclosed
EP-0511879-B1 Pyrazine derivatives OTSUKA PHARMA CO LTD (JP) 1995-03-22 EP disclosed
EP-0279150-A1 5-Oxy-substituted-3-aminochroman compounds, processes for their preparation, pharmaceutical compositions containing them and methods of treatment therewith ASTRA LAKEMEDEL AKTIEBOLAG (SE) 1988-08-24 EP disclosed
WO-1988004654-A1 5-HYDROXY-3-AMINOCHROMAN COMPOUNDS, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF TREATMENT THEREWITH Astra Läkemedel Aktiebolag (SE) 1988-06-30 WO disclosed
US-4229274-A PHOTOINITIATOR, PHOTOSENSITIZER, QUENCHER, AND COMPOUNDS CONTAINING ACRYLYLOXY GROUPS PPG INDUSTRIES, INC. (US) 1980-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR CYP3A4 447/4885TP53 889/4885MAOB 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.